Table 2.

Seropositive adult subjects in different age groups (median, range of years); percentage of additional T-lymphocyte (T-cell)-reactivity and virus neutralization test (VNT) in the number of subjects tested. n.a.: not available (vaccination does not trigger N-antibody production).

	Viramed					Roche
Age group	Number of subjects (n; median age; range age)	Antibody signatures	T-cell- reactivity	VNT	Number of subjects (n; median age; range age)		Antibody signatures	T-cell- reactivity	VNT
18–60 years; recovered subjects	29; 29; 22–59	18x N, S1, S2; 7x N, S1; 3x N; 1x S1, S2	79.31%	89.66%		27; 43; 22–59;	18x N, S1,S2; 7x N, S1; 2x N;	77.78%	92.59%
18–60 years; subjects after vaccination	21; 47; 26–59;	18x S1,S2; 3x S1	80.95%	95.24%		n.a.	n.a.	n.a.	n.a.
60+ years; recovered subjects	12; 81.5; 61–99;	8x N,S1,S2; 2x N,S1; 1x S1, S2; 1x S1	75,00%	91.67%		11; 79; 61–99	8x N, S1, S2; 2x N, S1; 1x N	90%	100%
60+ years; subjects after vaccination	11; 73; 61–93;	8x S1,S2; 3x S1	81.82%	90.91%		n.a.	n.a.	n.a.	n.a.